Your browser doesn't support javascript.
loading
Correction: Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study.
Ismaila, Afisi S; Rothnie, Kieran J; Wood, Robert P; Banks, Victoria L; Camidge, Lucinda J; Czira, Alexandrosz; Compton, Chris; Sharma, Raj; Millard, Shannon N; Massey, Olivia; Halpin, David M G.
Afiliação
  • Ismaila AS; Value Evidence and Outcomes, R&D Global Medical, GSK, 1250 South Collegeville Road, Collegeville, PA, USA. afisi.s.ismaila@gsk.com.
  • Rothnie KJ; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada. afisi.s.ismaila@gsk.com.
  • Wood RP; Value Evidence and Outcomes, R&D Global Medical, GSK, London, UK.
  • Banks VL; Real-World Evidence, Adelphi Real World, Bollington, Cheshire, UK.
  • Camidge LJ; Real-World Evidence, Adelphi Real World, Bollington, Cheshire, UK.
  • Czira A; Integrated Evidence Generation (Women's Health Care), Bayer PLC, Reading, UK.
  • Compton C; Real-World Evidence, Adelphi Real World, Bollington, Cheshire, UK.
  • Sharma R; Value Evidence and Outcomes, R&D Global Medical, GSK, London, UK.
  • Millard SN; Global Medical, GSK, London, UK.
  • Massey O; Global Medical, GSK, London, UK.
  • Halpin DMG; Real-World Evidence, Adelphi Real World, Bollington, Cheshire, UK.
Respir Res ; 25(1): 152, 2024 Apr 01.
Article em En | MEDLINE | ID: mdl-38561735

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article